Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-576 PK, Safety, and DDI with Galicaftor/Navocaftor in Healthy Volunteers
NCT05530278Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ABBV-576 in cystic fibrosis (CF) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started Sep 2022; status: completed.
02
Drugs
ABBV-576
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05530278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05530278.